New Phase III Data May Give Gilead A Leg Up In Genotype 3 HCV Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher SVR12 rate in genotype 3 patients seen than the 89% reported with a combo of Sovaldi and Bristol's Daklinza. Gilead plans US and EU filings of the combo during the fourth quarter.